About the bill
- Full Title
A bill to permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.
The bill’s title was written by its sponsor.
This is the first step in the legislative process.
7 cosponsors (7D) (show)(joined Apr 18, 2012)(joined Apr 18, 2012)(joined Apr 18, 2012)(joined Apr 18, 2012)(joined Apr 18, 2012)(joined Apr 18, 2012)(joined Apr 19, 2012)
- Committee Assignments
The committee chair determines whether a bill will move past the committee stage.
There have been no roll call votes related to this bill.
Links & tools
Click a format for a citation suggestion:
Civic Impulse. (2016). S. 2295 — 112th Congress: Patient Safety and Generic Labeling Improvement Act. Retrieved from https://www.govtrack.us/congress/bills/112/s2295
“S. 2295 — 112th Congress: Patient Safety and Generic Labeling Improvement Act.” www.GovTrack.us. 2012. July 28, 2016 <https://www.govtrack.us/congress/bills/112/s2295>
|title=S. 2295 (112th)
|accessdate=July 28, 2016
|author=112th Congress (2012)
|date=April 18, 2012
|quote=Patient Safety and Generic Labeling Improvement Act